532 related articles for article (PubMed ID: 25481458)
1. Rational design of biaryl pharmacophore inserted noscapine derivatives as potent tubulin binding anticancer agents.
Santoshi S; Manchukonda NK; Suri C; Sharma M; Sridhar B; Joseph S; Lopus M; Kantevari S; Baitharu I; Naik PK
J Comput Aided Mol Des; 2015 Mar; 29(3):249-70. PubMed ID: 25481458
[TBL] [Abstract][Full Text] [Related]
2. Rational design, synthesis, and biological evaluation of third generation α-noscapine analogues as potent tubulin binding anti-cancer agents.
Manchukonda NK; Naik PK; Santoshi S; Lopus M; Joseph S; Sridhar B; Kantevari S
PLoS One; 2013; 8(10):e77970. PubMed ID: 24205049
[TBL] [Abstract][Full Text] [Related]
3. 9-Arylimino noscapinoids as potent tubulin binding anticancer agent: chemical synthesis and cellular evaluation against breast tumour cells.
Patel AK; Meher RK; Nagireddy PK; Pragyandipta P; Pedapati RK; Kantevari S; Naik PK
SAR QSAR Environ Res; 2021 Apr; 32(4):269-291. PubMed ID: 33687299
[TBL] [Abstract][Full Text] [Related]
4. Rational design, synthesis and biological evaluations of amino-noscapine: a high affinity tubulin-binding noscapinoid.
Naik PK; Chatterji BP; Vangapandu SN; Aneja R; Chandra R; Kanteveri S; Joshi HC
J Comput Aided Mol Des; 2011 May; 25(5):443-54. PubMed ID: 21544622
[TBL] [Abstract][Full Text] [Related]
5. Combined molecular dynamics and continuum solvent approaches (MM-PBSA/GBSA) to predict noscapinoid binding to γ-tubulin dimer.
Suri C; Naik PK
SAR QSAR Environ Res; 2015 Jun; 26(6):507-19. PubMed ID: 26274780
[TBL] [Abstract][Full Text] [Related]
6. Rational design of novel N-alkyl amine analogues of noscapine, their chemical synthesis and cellular activity as potent anticancer agents.
Meher RK; Pragyandipta P; Pedapati RK; Nagireddy PKR; Kantevari S; Nayek AK; Naik PK
Chem Biol Drug Des; 2021 Sep; 98(3):445-465. PubMed ID: 34051055
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and biological evaluation of novel biaryl type α-noscapine congeners.
Manchukonda NK; Naik PK; Sridhar B; Kantevari S
Bioorg Med Chem Lett; 2014 Dec; 24(24):5752-5757. PubMed ID: 25453814
[TBL] [Abstract][Full Text] [Related]
8. Synergistic interaction of N-3-Br-benzyl-noscapine and docetaxel abrogates oncogenic potential of breast cancer cells.
Dash SG; Kantevari S; Pandey SK; Naik PK
Chem Biol Drug Des; 2021 Sep; 98(3):466-479. PubMed ID: 34107169
[TBL] [Abstract][Full Text] [Related]
9. Rational design of 9-vinyl-phenyl noscapine as potent tubulin binding anticancer agent and evaluation of the effects of its combination on Docetaxel.
Dash SG; Suri C; Nagireddy PKR; Kantevari S; Naik PK
J Biomol Struct Dyn; 2021 Sep; 39(14):5276-5289. PubMed ID: 32608323
[TBL] [Abstract][Full Text] [Related]
10. Rational design of novel microtubule targeting anticancer drugs N-imidazopyridine noscapinoids: Chemical synthesis and experimental evaluation based on in vitro using breast cancer cells and in vivo using xenograft mice model.
Pragyandipta P; Pedapati RK; Reddy PK; Nayek A; Meher RK; Guru SK; Kantevari S; Naik PK
Chem Biol Interact; 2023 Sep; 382():110606. PubMed ID: 37330181
[TBL] [Abstract][Full Text] [Related]
11. Rational design, chemical synthesis and cellular evaluation of novel 1,3-diynyl derivatives of noscapine as potent tubulin binding anticancer agents.
Patel AK; Meher RK; Reddy PK; Pedapati RK; Pragyandipta P; Kantevari S; Naik MR; Naik PK
J Mol Graph Model; 2021 Jul; 106():107933. PubMed ID: 33991960
[TBL] [Abstract][Full Text] [Related]
12. Structural Basis of Noscapine Activation for Tubulin Binding.
Oliva MA; Prota AE; Rodríguez-Salarichs J; Bennani YL; Jiménez-Barbero J; Bargsten K; Canales Á; Steinmetz MO; Díaz JF
J Med Chem; 2020 Aug; 63(15):8495-8501. PubMed ID: 32657585
[TBL] [Abstract][Full Text] [Related]
13.
Meher RK; Nagireddy PKR; Pragyandipta P; Kantevari S; Singh SK; Kumar V; Naik PK
J Biomol Struct Dyn; 2022 Sep; 40(15):6725-6736. PubMed ID: 33627059
[TBL] [Abstract][Full Text] [Related]
14. Development of 1,3-diynyl derivatives of noscapine as potent tubulin binding anticancer agents for the management of breast cancer.
Meher RK; Pragyandipta P; Reddy PK; Pedaparti R; Kantevari S; Naik PK
J Biomol Struct Dyn; 2022; 40(23):13136-13153. PubMed ID: 34583618
[TBL] [Abstract][Full Text] [Related]
15. Antiproliferative Noscapinoids Bearing an Amidothiadiazole Scaffold as Apoptosis Inducers: Design, Synthesis and Molecular Docking.
Kumar Pedapati R; Pragyandipta P; Pranathi Abburi N; Chirra N; Kantevari S; Naik PK
Chem Biodivers; 2023 Feb; 20(2):e202201089. PubMed ID: 36690497
[TBL] [Abstract][Full Text] [Related]
16. Insights into the structure and tubulin-targeted anticancer potential of N-(3-bromobenzyl) noscapine.
Cheriyamundath S; Mahaddalkar T; Reddy Nagireddy PK; Sridhar B; Kantevari S; Lopus M
Pharmacol Rep; 2019 Feb; 71(1):48-53. PubMed ID: 30465924
[TBL] [Abstract][Full Text] [Related]
17. Rational design of novel anti-microtubule agent (9-azido-noscapine) from quantitative structure activity relationship (QSAR) evaluation of noscapinoids.
Santoshi S; Naik PK; Joshi HC
J Biomol Screen; 2011 Oct; 16(9):1047-58. PubMed ID: 21972248
[TBL] [Abstract][Full Text] [Related]
18. Molecular modeling reveals binding interface of γ-tubulin with GCP4 and interactions with noscapinoids.
Suri C; Joshi HC; Naik PK
Proteins; 2015 May; 83(5):827-43. PubMed ID: 25662919
[TBL] [Abstract][Full Text] [Related]
19. Molecular modelling and competition binding study of Br-noscapine and colchicine provide insight into noscapinoid-tubulin binding site.
Naik PK; Santoshi S; Rai A; Joshi HC
J Mol Graph Model; 2011 Jun; 29(7):947-55. PubMed ID: 21530342
[TBL] [Abstract][Full Text] [Related]
20. Identification of novel and improved antimitotic agents derived from noscapine.
Anderson JT; Ting AE; Boozer S; Brunden KR; Crumrine C; Danzig J; Dent T; Faga L; Harrington JJ; Hodnick WF; Murphy SM; Pawlowski G; Perry R; Raber A; Rundlett SE; Stricker-Krongrad A; Wang J; Bennani YL
J Med Chem; 2005 Nov; 48(23):7096-8. PubMed ID: 16279766
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
